cbdMD (YCBD) EBITDA (2016 - 2025)

cbdMD has disclosed EBITDA across 10 years of filings, most recently posting -$286288.0 for Q4 2025.

• EBITDA for Q4 2025 came in at -$286288.0, down 231.84% year-over-year; the trailing twelve-month figure through Dec 2025 was -$2.4 million (down 1.15% YoY), and the FY2025 annual result was -$2.2 million, up 34.77% from the prior year.
• EBITDA came in at -$286288.0 for Q4 2025 at cbdMD, up from -$685816.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$86272.0 in Q4 2024 to a low of -$33.1 million in Q2 2022.
• The 5-year median for EBITDA is -$1.7 million (2023), against an average of -$6.2 million.
• Across the five-year window, EBITDA sank 1328.74% in 2021 and surged 97.92% in 2024, its largest moves.
• cbdMD's EBITDA stood at -$25.1 million in 2021, then soared by 83.91% to -$4.0 million in 2022, then surged by 73.66% to -$1.1 million in 2023, then soared by 91.91% to -$86272.0 in 2024, then sank by 231.84% to -$286288.0 in 2025.
• The last three EBITDA figures came in at -$286288.0 (Q4 2025), -$685816.0 (Q3 2025), and -$904686.0 (Q2 2025), per Business Quant data.